

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
 REQUEST FOR FILING APPLICATION UNDER 37 C.F.R. 1.53(b)
 WITHOUT FILING FEE AND/OR WITHOUT EXECUTED INVENTOR'S DECLARATION

07/03/01

Assistant Commissioner for Patents
 Washington, DC 20231

Atty. Dkt. 620-148

Date: July 3, 2001

J1017 U.S. PTO
 09/897412
 07/03/01

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:

**USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC
 OBSTRUCTIVE PULMONARY DISEASE (COPD)**

without a filing fee and/or without an executed inventor's oath/declaration.

This application is made by the below identified inventor(s). Attached hereto are the following papers:

- ☐ Newly executed Declaration, ☐ Copy of Declaration from prior application, ☒ Abstract
 38 pages of specification and claims (including 10 numbered claims), and
 9 sheets of accompanying drawing/s.
☐ Record the attached assignment and return to the undersigned.
☐ Attached is a Power of Attorney.
☒ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

Application Number**Country****Day/Month/Year Filed**

0016441.8

GREAT BRITAIN

4 July 2000

, respectively, the entire content of which is hereby incorporated by reference in this application..

☐ Certified copy(ies) of foreign application(s) is/are attached.

☐ Certified copy(ies) filed on _____ in prior appln. no. _____ filed _____

☐ Petition filed in prior application to extend its life to insure co-pendency.

☐ The prior application is assigned to _____

☐ It is hereby requested that the Examiner consider the art cited in the above parent application(s) by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached, but pursuant to Rule 98(d) copies are not required.

☐ Applicant claims "small entity" status. ☐ "Small entity" statement attached.

☐ Please enter the attached and/or below preliminary amendment **prior** to calculation of filing fee:

☐ Also attached: ☐ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☐ Other:

1. Inventor: Richard J. DAVIS Great Britain
 (first) MI (last) (citizenship)
 Residence: (city) Hertfordshire (state/country) United Kingdom
 Mailing Address: Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom
 (Zip Code) SG8 5HD
2. Inventor: Keith J. PAGE Great Britain
 (first) MI (last) (citizenship)
 Residence: (city) Hertfordshire (state/country) United Kingdom
 Mailing Address: Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom
 (Zip Code) SG8 5HD

☐ See attached sheet(s) for additional inventor(s) information!!

Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.

1100 North Glebe Road, 8th Floor
 Arlington, Virginia 22201-4714
 Telephone: (703) 816-4000
 Facsimile: (703) 816-4100
 BJS:ms

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: _____